

**Amendments to the Specification**

Please replace the paragraph at page 1, lines 1 through 12, with the following amended paragraph:

**RELATED APPLICATIONS**

This application is a Continuation-in-part which claims priority to U.S. Application No. 09/734,490, filed on December 11, 2000, now abandoned, which is a Continuation of U.S. Application No. 09/029,459, filed June 25, 1998, now U.S. Patent No. 6,255,457, which is the U.S. National stage of International Application No. PCT/US96/14177, filed on September 5, 1996, published in English, which claims the benefit of U.S. Provisional Application No. 60/018,791, filed May 31, 1996, which claims the benefit of U.S. Provisional Application No. 60/018,301, filed May 24, 1996, and which claims priority to U.S. Application 08/582,917, filed January 4, 1996, now U.S. Patent No. 5,776,770, which claims the benefit of U.S. Provisional Application No. 60/003,453, filed September 8, 1995. The teachings of these applications are incorporated by reference in their entirety.

Please replace the paragraph at page 49, lines 19 through 23, with the following amended paragraph:

An antibody targeting lung caveolae in vivo could be useful as a carrier to achieve tissue-specific drug delivery. To test TX3.833 as a targeting vector, it was conjugated to various drugs and examined in vivo delivery of the immunoconjugate relative to the native drug. All TX3.833-drug conjugates showed greatly increased lung targeting up to 172-fold greater than drug alone (~~Supplemental Table 1~~) (Table 2).